



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,025	08/03/2007	Jose Javier Gomez Roman	4258-119	8556
23448	7590	06/18/2008	EXAMINER	
INTELLECTUAL PROPERTY / TECHNOLOGY LAW			DAVIS, MINH TAM B	
PO BOX 14329				
RESEARCH TRIANGLE PARK, NC 27709			ART UNIT	PAPER NUMBER
			1642	
			MAIL DATE	DELIVERY MODE
			06/18/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/563,025	ROMAN ET AL.	
	Examiner	Art Unit	
	MINH-TAM DAVIS	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 30 December 2005.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-34 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-34 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.

5) Notice of Informal Patent Application

6) Other: _____.

DETAILED ACTION

Claims 34-35 have been renumbered as claims 33-34, respectively, according to rule 126, because in the amended claims of 12/30/05, claim 33 was missing.

Accordingly, claims 1-34 are subjected to the following restriction requirement.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-12, 17, 19, 32, drawn to an in vitro diagnosis of renal cancer, by detecting Plexin-B1 protein.

Group 2, claim(s) 1-9, 13-16, 17, 19, 32-33, drawn to an in vitro diagnosis of renal cancer, by detecting Plexin-B1 mRNA.

Group 3, claims 17, 32, drawn to a method for an in vitro diagnosis of an individual potentially having renal cancer, i.e. at risk of having renal cancer, by detecting Plexin-B1 protein.

Group 4, claims 17, 32, drawn to a method for an in vitro diagnosis of an individual potentially having renal cancer, i.e. at risk of having renal cancer, by detecting Plexin-B1 mRNA.

Group 5, claims 18-19, drawn to an in vitro method for identifying or assessing the efficacy for renal cancer therapy of a compound that modulates Plexin-B1 protein.

Group 6, claims 18-19, drawn to an in vitro method for identifying or assessing the efficacy for renal cancer therapy of a compound that modulates Plexin-B1 gene.

Group 7, claims 19, 21, 23-24, drawn to a method for treating renal cancer, using Plexin-B1 nucleic acid.

Group 8, claims 19, 22, drawn to a method for treating renal cancer, using Plexin-B1 protein.

Group 9, claims 19, 23-24, drawn to a method for treating renal cancer, using an agonist of Plexin-B1 protein.

Group 10, claims 20, 25-26, 28, 30-31, drawn to Plexin-B1 nucleic acid.

Group 11, claims 25-26, 34, drawn to an agonist of Plexin-B1 protein, which is not an antibody.

Group 12, claims 25-26, drawn to a cytotoxic agent, which is not Plexin-B1 nucleic acid, protein, or agonist.

Group 13, claim 27, drawn to Plexin-B1 protein.

Group 14, claim 29, drawn to an antibody to Plexin-B1 protein.

The inventions listed as Groups 1-14 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding technical feature is a contribution over the prior art. The inventions listed as

groups 1-14 do not relate to a single general inventive concept because they lack the same or corresponding special technical feature. The technical feature of the claimed invention, the Plexin-B1 protein, is taught by Aurandt et al, 2002 (PNAS, USA, 99 (19): 12085-90, abstract only).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, LARRY HELMS can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH TAM DAVIS

June 9, 2008

/Larry R. Helms/

Supervisory Patent Examiner, Art Unit 1643